Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

Clinical Infectious Diseases

Volumn 53, Issue 4, 2011, Pages 341-348

  Chantarangsu, Soranun ^a   Mushiroda, Taisei ^b   Mahasirimongkol, Surakameth ^c   Kiertiburanakul, Sasisopin ^d   Sungkanuparph, Somnuek ^d   Manosuthi, Weerawat ^c   Tantisiriwat, Woraphot ^e   Charoenyingwattana, Angkana ^f   Sura, Thanyachai ^d   Takahashi, Atsushi ^b   Kubo, Michiaki ^b   Kamatani, Naoyuki ^b   Chantratita, Wasun ^d   Nakamura, Yusuke ^g  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b RIKEN   (Japan)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e SRINAKHARINWIROT UNIVERSITY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COILED COIL ALPHA HELICAL ROD PROTEIN1; NEVIRAPINE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CHROMOSOME 6P; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND;

ANTI-HIV AGENTS; CHROMOSOMES, HUMAN, PAIR 6; DRUG ERUPTIONS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIV INFECTIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LAMIVUDINE; LOGISTIC MODELS; NEVIRAPINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; STAVUDINE; THAILAND;

EID: 79961219567     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir403     Document Type: Review

References (31)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. US Department of Health and Human Services (DHHS), January 29, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 1 September 2009.
2. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-92. (Pubitemid 29058411)
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
4. de Maat MM, Ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59:457-62. (Pubitemid 37214954)
5. Metry DW, Lahart CJ, Farmer KL, et al. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44:354-7. (Pubitemid 32167665)
6. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-92. (Pubitemid 40409537)
7. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, et al. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6:65-9. (Pubitemid 351461023)
8. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-81. (Pubitemid 32744607)
9. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-71. (Pubitemid 40515849)
10. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapineassociated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14:2153-7.
11. Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2004.
12. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell counts. AIDS 2005; 19:97-9. (Pubitemid 40111026)
13. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540-1. (Pubitemid 351317299)
14. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-6. (Pubitemid 44162404)
15. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-5. (Pubitemid 46036947)
16. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19:139-46.
17. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359:789-99.
18. Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med 2009; 360:1718-28.
19. The Division of Acquired Immunodeficiency Syndrome (DAIDS). Division of AIDS table for grading the severity of adult and pediatric adverse events. December 2004. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/ documents/DAIDS-AE-GradingTable-FinalDec2004.pdf. Accessed 1 September 2009.
20. World Medical Association. Ethical principles for medical research involving human subjects. World Medical Association Declaration of Helsinki.WorldMedical Association General Assembly, October, 2004. Available at: http://www.wma.net/e/policy/pdf/17c.pdf. Accessed 1 September 2009.
21. Gunderson KL, Steemers FJ, Lee G, et al. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 2005; 37:549-54. (Pubitemid 40617286)
22. Ohnishi Y, Tanaka T, Ozaki K, et al.Ahigh-throughputSNPtyping system for genome-wide association studies. J Hum Genet 2001; 46:471-7. (Pubitemid 32744120)
23. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-51. (Pubitemid 27299787)
24. Aulchenko YS, Ripke S, Isaacs A, et al. GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007; 23:1294-6. (Pubitemid 47050548)
25. Hanley JA, McNeil BJ. Themeaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36. (Pubitemid 12142173)
26. Rosenberg AL. Recent innovations in intensive care unit riskprediction models. Curr Opin Crit Care 2002; 8:321-30.
27. The R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, 2007. http://www.r-project.org.
28. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-5. (Pubitemid 40202029)
29. Asumalahti K, Laitinen T, Itkonen-Vatjus R, et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. HumMol Genet 2000; 9:1533-42. (Pubitemid 30386708)
30. Asumalahti K, Veal C, Laitinen T, et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002; 11:589-97. (Pubitemid 34257495)
31. Kiertiburanakul S, Sungkanuparph S, Malathum K, et al. A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation. Open AIDS J 2009; 3:24-30.